Trials / Sponsors / Nasus Pharma
Nasus Pharma
Industry · 6 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Enrolling By Invitation | Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis Anaphylaxis, Allergy | Phase 1 / Phase 2 | 2025-11-03 |
| Enrolling By Invitation | FMXIN002 in Patients at Risk of Anaphylaxis Anaphylaxis Food | Phase 2 / Phase 3 | 2025-06-12 |
| Completed | Comparative Bioavailability of Intranasal Epinephrine Anaphylaxis, Anaphylactic Reaction | Phase 1 / Phase 2 | 2023-08-22 |
| Completed | COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID- COVID-19, Upper Respiratory Tract Infections | N/A | 2021-05-19 |
| Completed | A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder Opioid Overdose | Phase 1 | 2021-01-31 |
| Completed | Bioavailability of Nasal Epinephrine Anaphylaxis | Phase 1 | 2020-11-01 |